Dr. David Artis and colleagues have published breakthrough findings in Nature that have opened a newly targeted pathway, and ultimately, a new approach for the treatment of obesity and obesity-related diseases. Utilizing a wide array of high tech tools, the team discovered for the first time that ILC2s, a group of innate lymphoid cells, promote the "beiging" of white adipose tissue (a type of body fat) and limit obesity.
Since Dr. Michel Kahaleh joined the department, there has been a 175% increase in advanced endoscopic interventional procedures in gastroenterology as well as the launch of the first pancreatic program at NYP/WCM. Under his direction, there has also been a rise in the number of minimally invasive endoscopic techniques that are highly effective, safe, and spare patients from major surgeries.
Dr. Ype de Jong was interviewed on NY1 regarding recent public outreach about hepatitis C in New York. He also spoke about the rapidly evolving management of this serious disease that infects the liver through blood products, and which can cause cirrhosis and liver cancer.
In pregnant women, the diagnostic and therapeutic techniques used for gall stones, strictures, obstructions, or other conditions within the biliary or pancreatic ductal systems, has been problematical due to exposure to radiation for the mother and the fetus. Dr. Michel Kahaleh and his team have successfully modified endoscopic retrograde cholangiopancreatography (ERCP) to reduce the estimated fetal radiation exposure, thereby making the procedure safe for pregnant women.
This was the 22nd annual presentation of the DOM Investigator Award, which is presented to members of the Department of Medicine, below the rank of professor, who perform on an outstanding level in the areas of clinical and/or basic biomedical research. The award is generously supported by the Michael Wolk Foundation.
An internationally-recognized leader in the field of hepatitis C, Dr. Ira M. Jacobson (Chief, Division of Gastroenterology and Hepatology) has been at the forefront of hepatitis C for more than 20 years. His research has included numerous advances regarding therapies, often involving interferon.
Ira M. Jacobson, M.D., the lead investigator of the ADVANCE trial, reported breakthrough findings at the 61st Annual Meeting of the American Association for the Study of Liver Disease in Boston on November 2, 2010. Adding a protease inhibitor – telaprevir – to the standard first-time treatment given to patients with hepatitis C resulted in a superior success rate.
Physicians from The Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian/Weill Cornell Medical Center will reveal the most-up-to-date information on colorectal cancer screening guidelines, risk factors, and risk reduction. In addition, Katie Couric will be on hand to answer questions regarding colorectal cancer and the importance of screening, early detection, and prevention.
The AAP, founded in 1885, annually recognizes 55 individuals who have attained preeminence in medical research. Elected members have included Nobel laureates and members of the National Academy of Science, and encompass all field of medicine.
The American Liver Foundation, the nation's leading nonprofit organization for liver health promotion and disease prevention, has named Dr. Ira M. Jacobson as their Physician of the Year Award Recipient. He will be honored on September 27, 2007 at the Flavors of New York Culinary Gala at the Pierre Hotel.
